

In the Specification

At page 1, after the title, please insert the following paragraph:

RELATED APPLICATIONS

This application is a divisional of U.S. Application No. 08/709,838, filed September 10, 1996.---

In the Claims

Please cancel Claims 1-15, 18 and 22-59, amend Claims 16, 17 and 19 - 21, and add new Claims 60 - 84 as follows:

16. (Amended) An isolated [mammalian CXCR3] human CXC Chemokine Receptor 3 (CXCR3) protein or functional variant thereof, wherein said protein or variant can selectively bind one or more chemokines and can mediate cellular signalling and/or a cellular response in [reponse] response thereto, and wherein said protein or variant is encoded by a nucleic acid which hybridizes under high stringency conditions to a second nucleic acid and the sequence of said second nucleic acid is selected from the group consisting of Figure 1 (SEQ ID NO:1) and a sequence complementary to Figure 1 (SEQ ID NO:1).

17. (Amended) The isolated [mammalian] human CXCR3 protein or functional variant thereof of Claim 16, wherein [the mammal is a human and] the protein can selectively bind one or more chemokines selected from the group consisting of human IP-10 and human Mig.

19. (Amended) An isolated human CXC Chemokine Receptor 3 (CXCR3) [CXCR3] protein encoded by the nucleic acid illustrated in Figure 1 (SEQ ID NO:1).

20. (Amended) [The] An isolated human CXC Chemokine Receptor 3 (CXCR3) [CXCR3] protein [of Claim 19 having] comprising an amino acid sequence as set forth in Figure 2 (SEQ ID NO:2).

- 5
21. (Amended) A fusion protein comprising a [mammalian CXCR3] human CXC Chemokine Receptor 3 (CXCR3) protein, wherein the amino acid sequence of said CXCR3 protein is a sequence encoded by the nucleic acid illustrated in Figure 1 (SEQ ID NO:1).

Please add the following claims:

- 6
---60. A fusion protein comprising a human CXC Chemokine Receptor 3 (CXCR3) protein wherein the amino acid sequence of said CXCR3 protein consists of the amino acid sequence of Figure 2 (SEQ ID NO:2).

61. A fusion protein comprising a human CXC Chemokine Receptor 3 (CXCR3) protein or functional variant thereof, wherein said CXCR3 protein or variant can selectively bind one or more chemokines and can mediate cellular signalling and/or a cellular response in response thereto, and wherein said CXCR3 protein or variant is encoded by a nucleic acid which hybridizes under high stringency conditions to a second nucleic acid and the sequence of said second nucleic acid is selected from the group consisting of Figure 1 (SEQ ID NO:1) and a sequence complementary to Figure 1 (SEQ ID NO:1).

62. The fusion protein of Claim 61, wherein said CXCR3 protein or variant can selectively bind one or more chemokines selected from the group consisting of human IP-10 and human Mig.

63. An isolated human CXC Chemokine Receptor 3 (CXCR3) protein or variant thereof, wherein the amino acid sequence of said CXCR3 protein or variant is at least about 90 % identical to that of the protein shown in Figure 2 (SEQ ID NO:2), said protein or variant comprises the extracellular N-terminal segment of the protein shown in Figure 2 (SEQ ID NO:2), and said protein or variant can selectively bind one or more chemokines selected from the group consisting of IP-10 and Mig and mediate cellular signalling and/or a cellular response in response thereto.

- 500
42

11.65.

12 ~~66.~~

13
67.

14
~~68.~~

15
69.

14 70.

17
71.

18

~~72.~~

The isolated human CXCR3 protein of Claim ~~71~~¹⁷, wherein the label is a radioisotope, a spin label, an enzyme label, a fluorescent label, a chemiluminescent label, an antigen or epitope label.

19

~~73.~~

The fusion protein of Claim ~~21~~⁵, wherein said fusion protein is labeled with a detectable label.

20

~~74.~~

The fusion protein of Claim ~~73~~¹⁹, wherein the label is a radioisotope, a spin label, an enzyme label, a fluorescent label, a chemiluminescent label, an antigen or epitope label.

21

~~75.~~

The fusion protein of Claim ~~60~~⁶, wherein said fusion protein is labeled with a detectable label.

22

~~76.~~

The fusion protein of Claim ~~75~~²¹, wherein the label is a radioisotope, a spin label, an enzyme label, a fluorescent label, a chemiluminescent label, an antigen or epitope label.

23

~~77.~~

The fusion protein of Claim ~~61~~⁷, wherein said fusion protein is labeled with a detectable label.

24

~~78.~~

The fusion protein of Claim ~~77~~²³, wherein the label is a radioisotope, a spin label, an enzyme label, a fluorescent label, a chemiluminescent label, an antigen or epitope label.

25

~~79.~~

The fusion protein of Claim ~~62~~⁸, wherein said fusion protein is labeled with a detectable label.

26

~~80.~~

The fusion protein of Claim ~~79~~²⁵, wherein the label is a radioisotope, a spin label, an enzyme label, a fluorescent label, a chemiluminescent label, an antigen or epitope label.

27

~~81.~~

The isolated human CXCR3 protein or variant thereof of Claim ~~63~~⁹, wherein said protein is labeled with a detectable label.

28
82.

The isolated human CXCR3 protein or variant thereof of Claim ~~81~~²⁷, wherein the label is a radioisotope, a spin label, an enzyme label, a fluorescent label, a chemiluminescent label, an antigen or epitope label.

29
83.

The fusion protein of Claim ~~64~~¹⁰, wherein said fusion protein is labeled with a detectable label.

30
84.

The fusion protein of Claim ~~83~~²⁹, wherein the label is a radioisotope, a spin label, an enzyme label, a fluorescent label, a chemiluminescent label, an antigen or epitope label.---

REMARKS

The subject application is a divisional of Application No. 08/709,838. Original Claims 1-15, 18 and 22-59 have been canceled. Remaining Claims 16, 17 and 19-21 are directed to the invention of Group II, drawn to an isolated protein and fusion protein, as defined in the Restriction Requirement set forth in the Office Action dated July 14, 1997, which issued in parent Application No. 08/709,838. New Claims 60 - 84 have been added, and are directed to the invention of Group II.

Support for new Claims 63 and 64 can be found in the subject application (see e.g., page 17, lines 6-12 and Figure 2 for support for the recitation of proteins including the N-terminal extracellular domain and page 19, lines 21-25 for support for the recitation of 90% amino acid sequence identity). Support for labeled proteins, including fusion proteins, can be found in the subject application at page 17, lines 13-21.